In vitro Generation of Dendritic Cell - Breast Cancer Cell Hybrids For Induction of Cellular Immunity
Keywords:
Dendritic cells, T lymphocyte, NK cell, MCF-7, breast cancerAbstract
Dendritic cells (DCs) of cancer patients are unable to effectively process and present tumor associated antigens to immune cells, resulting in a spread of cancer cells. Our study was to enhance in vitro efficacy of DCs to further induce activities of T lymphocytes and Natural Killer (NK) cells for inhibition/reduction of a growth of a breast cancer cell line (MCF-7). Human monocytes, derived from buffy coat of six normal blood donors, were positively selected and generated DCs by culturing with recombinant GM-CSF and IL-4 for 6 days. Human monocyte-derived DCs were determined by a decrease in a level of CD14 and an increase in CD11c and HLA-DR levels by flow cytometry. The DCs were further pulsed with breast cancer cell lines (MCF-7) to generate DCs - MCF-7 tumor fusion cells with a mean success rate at 34.67%. The DCs - MCF-7 fusion cells were able to stimulate T cell proliferation as well as to enhance NK cells activities to kill MCF-7 from an average of 22.45% to 72.00% and 22.91% to 65.69%, respectively. Our study demonstrated a model for in vitro generation of effective human monocyte derived DCs - tumor fusion cells and a possibility to further develop alternative method to treat cancer patients.
References
สถาบันมะเร็งแห่งชาติ, กรมการแพทย์ กระทรวงสาธารณสุข. ทะเบียนมะเร็งระดับโรงพยาบาล พ.ศ. 2558. กรุงเทพฯ: บริษัท พรทรัพย์การพิมพ์ จำกัด; 2560.
Dalgleish AG, Browning MJ. Tumor immunology: immunotherapy and cancer vaccines. New York: Cambridge University Press; 1996.
Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-26.
Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-61.
Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, et al. Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010; 2010: 516768. (14 p.).
Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 2002; 104: 14-20.
Roos DS, Duchala CS, Stephensen CB, Holmes KV, Choppin PW. Control of virus-induced cell fusion by host cell lipid composition. Virology 1990; 175: 345-57.
Lentz BR. PEG as a tool to gain insight into membrane fusion. Eur Biophys J 2007; 36: 315-26.
Turksen K, editor. Embryonic stem cells: methods and protocols. 2nd ed. Totowa, N.J.: Humana Press; 2002.
Aguilar PS, Baylies MK, Fleissner A, Helming L, Inoue N, Podbilewicz B, et al. Genetic basis of cell-cell fusion mechanisms. Trends Genet 2013; 29: 427-37.
Davidson RL, O'Malley KA, Wheeler TB. Polyethylene glycol-induced mammalian cell hybridization: effect of polyethylene glycol molecular weight and concentration. Somatic Cell Genet 1976; 2: 271-80.
Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10: 4699-708.
Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27: 452-9.
Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005; 11: 7891-900.
Koido S, Hara E, Homma S, Namiki Y, Ohkusa T, Gong J, et al. Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol 2009; 2009: 657369. (13 p.).
Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-29.
Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, et al. Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy 2014; 6: 349-60.
Allahverdiyev A, Tari G, Bagirova M, Abamor ES. Current approaches in development of immunotherapeutic vaccines for breast cancer. J Breast Cancer 2018; 21: 343-53.
Gong J, Apostolopoulos V, Chen D, Chen H, Koido S, Gendler SJ, et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000; 101: 316-24.
Koido S, Hara E, Torii A, Homma S, Toyama Y, Kawahara H, et al. Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusion of autologous dendritic cells and metastatic colorectal cancer cells. Int J Cancer 2005; 117: 587-95.
Mou Y, Xie H, Huang X, Han W, Ni Y, Su H, et al. Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine. Oncol Lett 2013; 6: 1799-803.
Koido S. Dendritic-tumor fusion cell-based cancer vaccines. Int J Mol Sci 2016; 17: 828. (16 p.).
